Literature DB >> 35201508

Toxic and metabolic leukoencephalopathies in emergency department patients: a primer for the radiologist.

Neal R Shah1, Shahrzad Tavana2, Akwasi Opoku3, Douglas Martin2.   

Abstract

One of the most common chief complaints in the emergency department (ED) is altered mental status (AMS). Imaging plays a critical role in triaging patients and identifying the etiology of AMS. Toxic and metabolic etiologies are one of the primary differential categories for AMS, leading to toxic leukoencephalopathies. Toxic leukoencephalopathies are white matter disorders that result from either exogenous or endogenous sources. Common exogeneous causes of toxic leukoencephalopathy include drugs of abuse (heroin and cocaine), alcohol, inhaled gases (carbon monoxide), industrial agents (pesticides, toluene, ethylene glycol), and neurotoxic medications (methotrexate, metronidazole, vigabatrine, etc.); endogenous causes include hyper- and hypoglycemia, hyperammonemia, hyponatremia, and uremia. The imaging findings of toxic leukoencephalopathies manifest through a combination of vasogenic and cytotoxic edema, resulting in white matter patterns. These white matter patterns have been found to be pathognomonic. In the ED setting, it is imperative to develop a diagnosis based off of the imaging due to the lack of history and context that is typically provided with a chief complaint of altered mental status (AMS). To offer expeditious and accurate diagnosis, we present the classic imaging features of toxic leukoencephalopathies and correlate these imaging findings with pathophysiology.
© 2022. American Society of Emergency Radiology.

Entities:  

Keywords:  Altered mental status; Neuroradiology; Toxic and metabolic leukoencephalopathy

Mesh:

Substances:

Year:  2022        PMID: 35201508     DOI: 10.1007/s10140-022-02032-6

Source DB:  PubMed          Journal:  Emerg Radiol        ISSN: 1070-3004


  35 in total

Review 1.  Neuroimaging in drug and substance abuse part II: opioids and solvents.

Authors:  Jessica Borne; Roy Riascos; Hugo Cuellar; Daniel Vargas; Rafael Rojas
Journal:  Top Magn Reson Imaging       Date:  2005-06

Review 2.  Wernicke Encephalopathy-Clinical Pearls.

Authors:  Shirshendu Sinha; Archish Kataria; Bhanu Prakash Kolla; Nuria Thusius; Larissa L Loukianova
Journal:  Mayo Clin Proc       Date:  2019-06       Impact factor: 7.616

3.  Different routes of heroin intake cause various heroin-induced leukoencephalopathies.

Authors:  Mei-Yun Cheng; Shy-Chyi Chin; Yen-Chung Chang; Tony Wu; Siew-Na Lim; Hsiang-Yao Hsieh; Jung-Lung Hsu; Chun-Wei Chang; Wei-En Johnny Tseng; Han-Tao Li; Hsing-I Chiang; Bao-Luen Chang; Meng-Han Tsai; Long-Sun Ro
Journal:  J Neurol       Date:  2018-11-26       Impact factor: 4.849

Review 4.  Potentially Reversible and Recognizable Acute Encephalopathic Syndromes: Disease Categorization and MRI Appearances.

Authors:  Y Koksel; A M McKinney
Journal:  AJNR Am J Neuroradiol       Date:  2020-07-02       Impact factor: 3.825

5.  Cocaine increases the endothelial release of immunoreactive endothelin and its concentrations in human plasma and urine: reversal by coincubation with sigma-receptor antagonists.

Authors:  U Wilbert-Lampen; C Seliger; T Zilker; R M Arendt
Journal:  Circulation       Date:  1998-08-04       Impact factor: 29.690

6.  Cocaine-induced recurrent leukoencephalopathy.

Authors:  Alejandra González-Duarte; Ricardo Williams
Journal:  Neuroradiol J       Date:  2013-11-07

7.  Role of nitric oxide in cocaine-induced acute hypertension.

Authors:  W Mo; A K Singh; J A Arruda; G Dunea
Journal:  Am J Hypertens       Date:  1998-06       Impact factor: 2.689

Review 8.  Cocaine and ANCA associated vasculitis-like syndromes - A case series.

Authors:  Sujith Subesinghe; Sander van Leuven; Leena Yalakki; Shirish Sangle; David D'Cruz
Journal:  Autoimmun Rev       Date:  2017-11-03       Impact factor: 9.754

Review 9.  Multifocal leukoencephalopathy in cocaine users: a report of two cases and review of the literature.

Authors:  Reza Vosoughi; Brian J Schmidt
Journal:  BMC Neurol       Date:  2015-10-19       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.